- ¥158bn
- ¥108bn
- ¥97bn
Table: Kissei Pharm -Q1 group results
2026 6-month group forecast
Announcement For Opnion By European Authorities On Tavneos
Amgen up after EMA recommends revoking marketing authorization for rare-disease drug
Submission Of New Drug Application For Acute Myeloid Leukemia Treatment "Olutasidenib" In Japan
Currently Examining Financial Impact Of Rapid Safety Communication Regarding Tavneos (Generic Name Avacopan)
Advisory: Incorrectly tagged Kissei alert withdrawn
Amgen's rare disease drug linked to deaths, liver injuries in Japan, Kissei reports (updated)
Brief: 20 People In Japan Who Took Amgen's Tavneos Have Died, And At Least 22 Developed A Potentially Fatal Liver Injury, As Per Kissei Pharmaceutical- WSJ
Table: Kissei Pharm -2025/26 parent results
Table: Kissei Pharm -2025/26 group results
Licensing Agreement For "Olutasidenib" With Orient Europharma In Taiwan
Yselty Tablets 100Mg To Launch In Japan For Uterine Fibroids
Table: Kissei Pharm - 9-MTH group results
Marketing Authorization Approval In Japan For Yselty Tablets 100Mg, Oral Gnrh Antagonist, Indicated For Uterine Fibroids
Table: Kissei Pharm - 6-MTH group results
Licensing Agreement With Viridian Therapeutics For "Veligrotug" And "Vrdn-003" In Treatment Of Thyroid Eye Disease
Table: Kissei Pharm -Q1 group results
Table: Kissei Pharm -2024/25 group results